Neurotech International (ASX:NTI) has announced that Professor Allan Cripps AO has been appointed as a non-executive director.
Professor Cripps is currently a Professor Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University. He is also a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland.
The focus of Professor Cripps’ research activities over the last five decades has been in the field of immunology and inflammation. In 2015, he was awarded an Officer of the Order of Australia (AO) in recognition of his contributions to mucosal immunisation, public health and higher education.
Professor Cripps has experience in the development of immunity in children and mucosal immune mechanisms. In recent years, he has made a significant contribution to the field of immunology through translational research and human clinical studies.
Professor Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer-reviewed scientific papers and presented at many national and international scientific conferences.
“I am very pleased to have a scientist of the calibre of Professor Cripps joining the board of Neurotech at such an important juncture in the company’s transition from preclinical to clinical studies”, said Brian Leedman, chairman of Neurotech International.
“His appointment fills an obvious void in the board’s collective experience as the company increases expenditure in the scientific research of our unique cannabis strains for the treatment of neurological disorders.”
Professor Cripps said, “I am honoured to be joining the Board of Neurotech International at this exciting time as clinical research is commencing with low-level THC cannabis plant strains, initially in children with Autism and with potential broader application of these strains in other neurological and inflammatory disorders.”